Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TOFA (MDL14514) 是有效的乙酰辅酶 A 羧化酶-α (ACCA)的变构抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 236 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 578 | 现货 | ||
25 mg | ¥ 1,130 | 现货 | ||
50 mg | ¥ 2,120 | 现货 | ||
100 mg | ¥ 3,500 | 现货 | ||
200 mg | ¥ 4,970 | 现货 | ||
500 mg | ¥ 7,790 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 425 | 现货 |
产品描述 | TOFA (MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). |
体外活性 | TOFA inhibits the proliferation of the cancer cells examined in a time and dose dependent manner, arrests the cells in the G0/G1 cell cycle phase and induces apoptosis. Acetyl-CoA-carboxylase-α (ACCA) is a key enzyme in the regulation of fatty acids synthesis. Inhibition of ACCA by TOFA decreases fatty acid synthesis and induces caspase activation and cell death in most PCa cell lines. TOFA (5-tetradecyloxy-2-furoic acid) is cytotoxic to lung cancer cells NCI-H460 and colon carcinoma cells HCT-8 and HCT-15, with an IC50 at approximately 5.0, 5.0, and 4.5 μg/mL, respectively. TOFA at 1.0–20.0 μg/mL effectively blocks fatty acid synthesis and induces cell death in a dose-dependent manner. TOFA is found to be cytotoxic to COC1 and COC1/DDP cells with IC50 values of ~26.1 and 11.6 μg/mL, respectively. |
体内活性 | The tumor growth rate is signifi?cantly inhibited by TOFA compared with the DMSO treated control mice (1649±356.3 vs. 5128±390.4 mm3. No toxicity is observed in the heart, liver, spleen, lung, kidney and intestinal tissues. TOFA inhibits COC1/DDP cell growth in ovarian tumor mouse xenografts. By inhibiting ACC, TOFA may be a promising small molecule agent for ovarian cancer therapy. |
细胞实验 | NCI-H460, human lung cancer cells, and HCT-8 and HCT-15 cells (5,000/well) are seeded in 96-well plates overnight and then exposed to TOFA at indicated concentrations (0, 1, 5, 10, 20, 50 μg/mL) for 72 hours. Viable cells are detected using MTT assay[1]. |
别名 | MDL14514, RMI14514 |
分子量 | 324.45 |
分子式 | C19H32O4 |
CAS No. | 54857-86-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.88 mg/mL (21.19 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.0821 mL | 15.4107 mL | 30.8214 mL | 77.0535 mL |
5 mM | 0.6164 mL | 3.0821 mL | 6.1643 mL | 15.4107 mL | |
10 mM | 0.3082 mL | 1.5411 mL | 3.0821 mL | 7.7053 mL | |
20 mM | 0.1541 mL | 0.7705 mL | 1.5411 mL | 3.8527 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TOFA 54857-86-2 Metabolism Acetyl-CoA Carboxylase MDL14514 inhibit RMI-14514 ACC, Acetyl Coenzyme A Carboxylase RMI 14514 Inhibitor RMI14514 MDL-14514 MDL 14514 inhibitor